Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Employees - 14000, CEO - Anshul Thakral, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 0.73, Piotroski Score(max is 10): 5, Working Capital: $-40100000, Total Assets: $2714900000, Retained Earnings: $-1420000000, EBIT: 2900000, Total Liabilities: $2190700000, Revenue: $2676500000

AryaFin Target Price - $4.14 - Current Price $ - Analyst Target Price $